Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
1 finding from 1 review
Kidney failure progression: eGFR (mL/min/1.73m²) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Proportion of participants diagnosed with hypertension at trial completion · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
The review found no eligible studies for this question.
1 finding from 1 review
Intradialytic hypotension · people with CKD requiring dialysis
It is very uncertain whether dihydropyridine calcium channel blockers changes intradialytic hypotension compared with other antihypertensives (very low certainty).
1 finding from 1 review
Maternal admission to intensive care · pregnant women with diastolic hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal admission to intensive care · pregnant women with chronic or gestational hypertension
Setting of BP measurement: self‐measurement showed no clear difference in maternal admission to intensive care compared with conventional clinic measurement (low certainty).
1 finding from 1 review
Survival (overall and disease‐ specific) · women with stage IIIc or IV ovarian cancer
It is very uncertain whether ultra‐radical (extensive) surgery changes survival (overall and disease‐ specific) compared with standard surgery (very low certainty).
1 finding from 1 review
Progression‐free survival · women with stage IIIc or IV ovarian cancer
It is very uncertain whether ultra‐radical (extensive) surgery changes progression‐free survival compared with standard surgery (very low certainty).
1 finding from 1 review
Disease-free survival · women with stage IIIc or IV ovarian cancer
It is very uncertain whether ultra‐radical (extensive) surgery changes disease‐free survival compared with standard surgery (very low certainty).
1 finding from 1 review
Rate of optimal cytoreduction · women with stage IIIc or IV ovarian cancer
1 finding from 1 review
no estimate extracted
Studies not reported
High
Recurrence · women with stage IIIc or IV ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
(Loco)regional control · women with stage IIIc or IV ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Perioperative mortality · women with stage IIIc or IV ovarian cancer
It is very uncertain whether ultra‐radical (extensive) surgery changes adverse event: perioperative mortality compared with standard surgery (very low certainty).
1 finding from 1 review
Adverse event: serious postoperative morbidity · women with stage IIIc or IV ovarian cancer
It is very uncertain whether ultra‐radical (extensive) surgery changes adverse event: serious postoperative morbidity compared with standard surgery (very low certainty).
1 finding from 1 review
Quality of life · women with stage IIIc or IV ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · people with diabetes and kidney disease
It is very uncertain whether angiotensin receptor blocker (ARB) changes all‐cause death Median compared with another ARB (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in cardiovascular death Median compared with another ARB (low certainty).
1 finding from 1 review